Quetiapine XR for Cognitive and Functional Disability in Clinically Stable Patients With Bipolar Disorder
Status:
Terminated
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
Quetiapine has been reported to have beneficial cognitive effects in several randomized
controlled trials in schizophrenia. It has not yet been studied in bipolar disorder, but
promising results from the use of extended release quetiapine for the maintenance treatment
of bipolar disorder suggests that its cognitive benefits could be detected. Moreover,
quetiapine has been shown to have direct beneficial effects on performance-based measures of
social competence in schizophrenia and to improve quality of life (QoL) in bipolar
depression. The investigators propose to study quetiapine augmentation of mood stabilizer
monotherapy in clinically stable patients with bipolar disorder. This will be a randomized,
placebo controlled trial, with attentional impairments as the primary outcome and other
cognitive performance variables and measures of social and everyday living skills, as well as
subjective QoL, as the secondary outcomes.